Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 Tablet in Obese Subjects
NCT06841445Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Apr 2025; status: completed.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06841445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841445.